Netherlands-based Cristal Therapeutics has launched a Phase Ib clinical programme to assess its nanomedicine candidate CriPec-docetaxel for the treatment of solid tumours.

CriPec-docetaxel is being developed as a new drug modality to entrap a clinically validated chemotherapy, docetaxel (Taxotere), as therapeutic payload into nanoparticles.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Designed to allow increased tumour accumulation and local release of the drug, the candidate is intended to enhance therapeutic efficacy and overcome challenges such as toxic systemic side-effects associated with existing docetaxel products.

In addition to evaluation of the distribution and uptake of the nanomedicine candidate, Phase Ib programme will determine an optimal frequency and dosing schedule for Phase II clinical efficacy trials.

Cristal Therapeutics CEO and co-founder Dr Joost Holthuis said: “Progressing CriPec-docetaxel to a Phase Ib programme is an important milestone, and highlights the unique preliminary safety and pharmacokinetic data produced from the Phase Ia study.

“This highlights the unique preliminary safety and pharmacokinetic data produced from the Phase Ia study.”

“We look forward to the results of the consolidated Phase I programme.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The preliminary positive data obtained from the open-label, safety and pharmacokinetic Phase Ia trial indicated favourable safety and tolerability of the nanomedicine.

Furthermore, the results revealed that CriPec-docetaxel could be given at therapeutic dose levels.

In addition, the nanomedicine candidate is reported to have shown improved pharmacokinetic profile, when compared with other docetaxel-based drug products such as Taxotere.

The Phase 1b programme is being performed at three clinical sites across the Netherlands and at the University Hospitals Leuven General Medical Oncology department in Belgium.